Skip directly to Accessibility Notice

Will These Tech Stock Valuations Last?

13 February 2020

 

Despite the coronavirus concerns that have hit commodity markets and, in turn, energy and basic materials stocks, U.S. tech stocks have posted strong returns to start the year. This continues their impressive streak from 2019. But are the current tech valuations sustainable?

In a recent market note, Brian Colello, Director of Technology, Media and Telecom Equity Research at Morningstar, noted that the median tech stock was 11% overvalued as of January 30. This was one of the highest price/fair value ratios since 2007, according to Colello. Certain sub-industries within tech are more overvalued than others, but a strong fourth quarter and January have erased some discounts to fair value, particularly in semiconductor stocks, which Morningstar viewed as undervalued through much of 2019.

Software companies Microsoft (MSFT) and ServiceNow (NOW), both VanEck Morningstar Wide Moat UCITS ETF (MOAT) holdings, have had their fair value estimate raised in recent weeks following strong quarterly results. Other companies that appeared attractive in 2019 have rallied, leaving the tech sector one to keep an eye on as the impact of the coronavirus on markets becomes known. Colello noted that some tech companies have provided wider bands of revenue guidance, but there is no clear-cut impact to upcoming earnings at this point.

MOAT’s underlying index, Morningstar Wide Moat Focus Index (“Moat Index”), remains underweight tech stocks due to its focus on valuations. Its underexposure benefited the strategy during the trade war-induced selloff in the fourth quarter of 2018. The Moat Index currently maintains overweights to the application software and semiconductor sub-industries within tech. Morningstar will reassess company valuations in March.

Tech Stocks Have Taken Off Since June

Tech Stocks Have Taken Off Since June

Source: Morningstar. Data 31/1/2018 – 31/1/2020. Past performance is no guarantee of future results. For illustrative purposes only.

Healthcare Stocks in Focus: No Major Overhaul Expected

The top sector overweight in the Moat Index remains healthcare, despite a slight decrease in weighting over the last few quarters. Despite solid sector fundamentals, U.S. healthcare stocks underperformed the U.S. market through 2019, driven largely by political rhetoric feeding fears around potential healthcare policy changes.

Damien Conover, Director of Healthcare Equity Research at Morningstar, noted in January that their healthcare coverage universe was slightly overvalued, with the median price/fair value estimate at a 5% premium to fair value. He added that these elevated valuations are being driven by certain sub-industries, such as devices and diagnostics, where some investors are turning in order to maintain some healthcare exposure while avoiding areas more impacted by policy uncertainty, such as pharmaceuticals. One fallout from the potential structural and policy changes in healthcare was the 2019 downgrade of many companies involved in pharmaceutical distribution.

Conover noted that pockets of undervalued stocks within the sector exist. Drug and biotech industries present the most potential in this regard, due to market fears over potential policy limits on drug pricing power. Morningstar views these fears as overblown. According to Morningstar, growth in net drug prices (the price paid after discounts) has decelerated to below inflation, leaving Morningstar to view drug pricing as less of a problem. Therefore, even though some form of U.S. policy reform is probable, Morningstar does not believe a major overhaul is likely.

MOAT offers exposure to the pharmaceutical and biotech industries by holding wide moat stocks Bristol-Myers Squibb (BMY), Pfizer (PFE), Merk & Co (MRK), Biogen (BIIB), Gilead Sciences (GILD) and Amgen (AMGN).

Important Disclosure

This is a marketing communication. Please refer to the prospectus of the UCITS and to the KID before making any final investment decisions.

This information originates from VanEck (Europe) GmbH, which has been appointed as distributor of VanEck products in Europe by the Management Company VanEck Asset Management B.V., incorporated under Dutch law and registered with the Dutch Authority for the Financial Markets (AFM). VanEck (Europe) GmbH with registered address at Kreuznacher Str. 30, 60486 Frankfurt, Germany, is a financial services provider regulated by the Federal Financial Supervisory Authority in Germany (BaFin).

The information is intended only to provide general and preliminary information to investors and shall not be construed as investment, legal or tax advice VanEck (Europe) GmbH, VanEck Switzerland AG, VanEck Securities UK Limited and their associated and affiliated companies (together “VanEck”) assume no liability with regards to any investment, divestment or retention decision taken by the investor on the basis of this information. The views and opinions expressed are those of the author(s) but not necessarily those of VanEck. Opinions are current as of the publication date and are subject to change with market conditions. Certain statements contained herein may constitute projections, forecasts and other forward-looking statements, which do not reflect actual results. Information provided by third party sources is believed to be reliable and have not been independently verified for accuracy or completeness and cannot be guaranteed. Brokerage or transaction fees may apply.

VanEck Asset Management B.V., the management company of VanEck Morningstar US Sustainable Wide Moat UCITS ETF (the "ETF"), a sub-fund of VanEck UCITS ETFs plc, is a UCITS management company under Dutch law registered with the Dutch Authority for the Financial Markets (AFM). The ETF is registered with the Central Bank of Ireland, passively managed and tracks an equity index. Investing in the ETF should be interpreted as acquiring shares of the ETF and not the underlying assets. Investors must read the sales prospectus and key investor information before investing in a fund. These are available in English and the KIIDs/KIDs in certain other languages as applicable and can be obtained free of charge at www.vaneck.com, from the Management Company or from the following local information agents:
UK - Facilities Agent: Computershare Investor Services PLC
Austria - Facility Agent: Erste Bank der oesterreichischen Sparkassen AG
Germany - Facility Agent: VanEck (Europe) GmbH
Spain - Facility Agent: VanEck (Europe) GmbH
Sweden - Paying Agent: Skandinaviska Enskilda Banken AB (publ)
France - Facility Agent: VanEck (Europe) GmbH
Portugal - Paying Agent: BEST – Banco Eletrónico de Serviço Total, S.A.
Luxembourg - Facility Agent: VanEck (Europe) GmbH

Morningstar® US Sustainability Moat Focus Index is a trade mark of Morningstar Inc. and has been licensed for use for certain purposes by VanEck. VanEck Morningstar US Sustainable Wide Moat UCITS ETF is not sponsored, endorsed, sold or promoted by Morningstar and Morningstar makes no representation regarding the advisability in VanEck Morningstar US Sustainable Wide Moat UCITS ETF.
Effective December 17, 2021 the Morningstar® Wide Moat Focus IndexTM has been replaced with the Morningstar® US Sustainability Moat Focus Index.
Effective June 20, 2016, Morningstar implemented several changes to the Morningstar Wide Moat Focus Index construction rules. Among other changes, the index increased its constituent count from 20 stocks to at least 40 stocks and modified its rebalance and reconstitution methodology. These changes may result in more diversified exposure, lower turnover and longer holding periods for index constituents than under the rules in effect prior to this date.
It is not possible to invest directly in an index.

All performance information is based on historical data and does not predict future returns. Investing is subject to risk, including the possible loss of principal.

No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission of VanEck.

© VanEck (Europe) GmbH / VanEck Asset Management B.V.

1 - 3 of 3